IDEXX Laboratories, Inc. (IDXX) Stake Raised by DnB Asset Management AS

DnB Asset Management AS grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,860 shares of the company’s stock after buying an additional 3,500 shares during the quarter. DnB Asset Management AS’s holdings in IDEXX Laboratories were worth $3,418,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of IDXX. Vanguard Group Inc. boosted its holdings in IDEXX Laboratories by 4.0% in the second quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock worth $1,495,488,000 after purchasing an additional 354,024 shares during the last quarter. BlackRock Inc. boosted its holdings in IDEXX Laboratories by 10.5% in the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock worth $1,146,142,000 after purchasing an additional 673,347 shares during the last quarter. Koch Industries Inc. boosted its holdings in IDEXX Laboratories by 44,533.1% in the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after purchasing an additional 1,396,113 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in IDEXX Laboratories by 38.6% in the second quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock worth $218,224,000 after purchasing an additional 376,300 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in IDEXX Laboratories by 42.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock worth $211,567,000 after purchasing an additional 392,790 shares during the last quarter. Hedge funds and other institutional investors own 86.61% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $173.24 on Friday. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77. IDEXX Laboratories, Inc. has a fifty-two week low of $116.54 and a fifty-two week high of $173.82. The stock has a market cap of $15,100.00, a P/E ratio of 56.25, a P/E/G ratio of 2.31 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. During the same period last year, the firm earned $0.62 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. analysts expect that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.

In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 2,160 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $167.03, for a total value of $360,784.80. Following the transaction, the chief executive officer now directly owns 1,077,112 shares in the company, valued at $179,910,017.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the completion of the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at $163,678,098.75. The disclosure for this sale can be found here. Insiders sold 130,160 shares of company stock worth $20,019,685 over the last quarter. Insiders own 2.77% of the company’s stock.

Several brokerages recently issued reports on IDXX. Stifel Nicolaus restated a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. BidaskClub upgraded shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. Finally, Canaccord Genuity restated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. IDEXX Laboratories currently has a consensus rating of “Hold” and a consensus price target of $173.67.

ILLEGAL ACTIVITY NOTICE: “IDEXX Laboratories, Inc. (IDXX) Stake Raised by DnB Asset Management AS” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/14/idexx-laboratories-inc-idxx-stake-raised-by-dnb-asset-management-as.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply